Author

H. G. Coleman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Assay:imaging· 1

Frequent Co-Authors

M. B. Loughrey· 2 shared P. Bankhead· 2 shared P. D. Dunne· 2 shared A. Gilmore· 1 shared A. M. McCorry· 1 shared C. Holohan· 1 shared D. B. Longley· 1 shared D. G. McArt· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

M. B. Loughrey

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of a semi-automated method for tumor budding assessment in colorectal cancer and comparison with manual methods

N. C. Fisher, M. B. Loughrey, H. G. Coleman, M. D. Gelbard, P. Bankhead, P. D. Dunne

This study develops a semi-automated method for tumor budding assessment in colorectal cancer and compares it with manual methods, finding strong correlation and higher detection rates with the new approach.

bioRxiv · Jun 17, 2021Pathology

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.

bioRxiv · Oct 23, 2017Cancer Biology